|
|
|
|
Therakos ECP-day
Clinical, regulatory and economic overview of THERAKOS® photopheresis
|
|
|
|
Rome, 29th
September 2016
Hilton Rome
Airport Hotel
|
|
|
|
|
|
The information
in this email is
intended only for
healthcare
professionals
in
Europe, the
Middle East and
Asia Pacific.
|
|
|
|
THERAKOS®
Photopheresis and
the Outcomes
|
|
|
|
10.15 –
10.45
|
Therakos’
support to the
photopheresis
clinical
evidence.
A Medical Affairs
overview
Francesca
Gennari,
Medical Affairs,
Therakos
|
|
|
|
10.45 –
11.15
|
THERAKOS®
Photopheresis in
the Rotherham
experience
Dr. Peter
Taylor,
Rotherham, UK
|
|
|
|
11.15 –
11.45
|
Treating
adult patients with
THERAKOS® CELLEX®
Photopheresis
System
Dr.
Francesco
Ipsevich,
Rome
|
|
|
|
11.45 –
12.15
|
Treating
pediatric patients
with THERAKOS®
CELLEX®
Photopheresis
System
Dr. Stefano
Ceccarelli,
Rome
|
|
|
|
THERAKOS®
Photopheresis and
Regulations
|
|
|
|
12.15 –
12.45
|
Structural, procedural and organizational requirements of the photopheresis procedure, according to the EU and national "cells and tissue" regulations
Dr. Aurora Vassanelli,
Verona
|
|
|
|
12.45 –
13.15
|
QUICK LUNCH
|
|
|
|
13.15 –
13.45
|
THERAKOS®
CELLEX®
Photopheresis
System compliance
with both “Cells
and Tissue” and
medicinal products
regulations.
Implications of CE
mark and drug
product
authorization on
patient’s
safety
Raquel
Carnero,
Regulatory Affairs,
Therakos
|
|
|
|
13.45 –
14.15
|
The
Quality management
of a photopheresis
procedure
Dr. Michele
Vacca,
Rome
|
|
|
|
THERAKOS®
Photopheresis and
Economics
|
|
|
|
14.15 –
14.45
|
An
analysis of the
overall cost of the
photopheresis
procedure
Dr. Ivo
Gentilini,
Bolzano
|
|
|
|
14.45 –
15.15
|
The
economic value of
an integrated
photopheresis
system
Oscar
Mesa,
Health &
Economics, Therakos
|
|
|
|
15.15 –
15.45
|
Therakos
Science and
Technology: the
Value of All-in-one
Support
Monica
Minguzzi,
Science &
Technology,
Therakos
Inês
Sa, Global
Advocacy &
Education,
Therakos
|
|
|
|
15.45
|
Wrap up and closure
|
|
|
|
|
|
|
|
